Two Guys, One Ticker

Two Guys, One Ticker

Two guys, one ticker at a time. Preston Hayes and Logan Pierce break down the base case, the bear case, and the bull case for the stocks worth talking about.

Two Guys, One Ticker

Ondas Holdings (ONDS): Base, Bear, and Bull Case

Episode discussion: Ondas Holdings reports record Q3 revenue but stock falls as analysts debate dilution and profitability path

Speakers’ claims: Preston Hayes and guests analyze Ondas Holdings (ONDS) following a record Q3 with $167.5 million in revenue and an $835 million backlog. The speakers outline a base case where the company transitions from a roll-up to a defense prime valuation, a bear case citing dilution and margin compression, and a bull case highlighting a Palantir partnership and aggressive 2027 guidance. Key concerns include a nearly five-fold increase in share count due to acquisitions and changes in adjusted EBITDA definitions. The discussion contrasts strong top-line growth with skepticism regarding revenue quality and the sustainability of profitability targets.

DefenseM&AAutonomous Systems
12 min0 assets10 claims to verify
Two Guys, One Ticker

Definium Therapeutics (DFTX): Base, Bear, and Bull Case

Episode discussion: Two Guys One Ticker analyzes Definium Therapeutics ahead of Q3 earnings, outlining base, bear, and bull cases for DFTX.

Speakers’ claims: Preston Hayes and Logan Pierce discuss Definium Therapeutics (DFTX) ahead of its Q3 earnings report on November 9, 2026. They highlight the company's recent stock performance, noting a 148% year-to-date gain despite a recent pullback from highs. The hosts review three positive Phase 3 clinical readouts for the lead asset DT120ODT in anxiety and depression, alongside Breakthrough Therapy Designations from the FDA. They outline a base case of steady regulatory progress, a bear case citing FDA and scheduling risks, and a bull case focused on the massive market opportunity for a first-approved psychedelic treatment. The episode concludes with an overview of analyst consensus, which rates all 19 covering analysts as buy with a consensus price target of $72.56.

BiotechClinical TrialsFDA Regulation
14 min1 assets10 claims to verify